Clinical trial
Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed…
NCT00360828 · H. Lee Moffitt Cancer Center and Research Institute, Other · Terminated
Key facts
| NCT number | NCT00360828 |
|---|---|
| Title | Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas |
| Official title | A Phase II Study of Irinotecan HCI in Patients With Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas |
| Lead sponsor | H. Lee Moffitt Cancer Center and Research Institute, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Astrocytoma, Glioma, Oligodendroglioma |
| Intervention type | Drug |
| Interventions | Irinotecan Hydrochloride (HCI) Treatment, Continued Irinotecan Hydrochloride (HCI) Treatment |
| Enrollment | 10 |
| Start date | Feb 1, 2006 |
| Primary completion | Oct 1, 2010 |
| Completion | Oct 1, 2010 |
| First posted | Aug 7, 2006 |
| Last update posted | Mar 23, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: